Wed, Apr 23, 2014, 11:46 AM EDT - U.S. Markets close in 4 hrs 14 mins

Recent

% | $
Quotes you view appear here for quick access.

J. C. Penney Company, Inc. Message Board

jonnisilver 11 posts  |  Last Activity: Apr 15, 2014 1:40 PM Member since: Feb 9, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The deep freeze has taken over small cap land. It has been a long time since small caps were out of vogue but the time has come. As the great rotation of capital shifts from high risk stocks to low risk, high dividend payers, many think the end has come for any investments in small caps. I am here to say that is not true. Over the past year, you could have closed your eyes and thrown a dart at a small cap and made a lot of money. Those times have changed, however there is still money to be made.

    You must now start analyzing the charts and buy at the key levels. For example, on no news, Rosetta Genomics Ltd. (NASDAQ:ROSG) has fallen from over $6.50 to $3.45. This monster drop is now crossing the 200 moving average and heading to gap fill at $3.20. This $3.20 level will be where the stock price has been cut in half as well as major support. At this discount, the stock becomes extremely attractive to tuck away a small position.

    Another biotech stock approaching a key level is OXiGENE Inc (NASDAQ:OXGN). Good news drove it to $5.40, however the risk adverse market has taken it down to $2.59. There is a key gap fill at $2.43 that offers a very intriguing risk to reward opportunity.

    Always remember small cap stocks are very high risk. Most likely the way to trade these plays is to be in, get a solid bounce and take profits.

    Gareth Soloway
    InTheMoneyStocks

  • One of the hottest stock sectors in 2013 was the bio-technology stocks. Leading bio-tech stocks such as Celgene Corp (CELG), Gilead Sciences Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Amgen Inc (AMGN) were some of the biggest winners last year. So far in 2014, this high growth industry group has been in correction mode. Many of the leading bio-tech stocks are now trading lower by 20.0 percent or more since the start of the new year. While it is safe to say that the bio-tech sector is severely oversold, this important industry group has not yet bottomed out.

    Traders and investors can expect minor bounces in the bio-tech stocks from current levels, but it is not a true bottom in the industry group just yet. Remember nothing in the stock market goes down or up in a straight line. One of the ways that traders and investors can play the entire bio-tech sector is to use and follow the iShares NASDAQ Biotechnology Index ETF (IBB). At this time, the IBB is signaling downside to the $202.00 level. This is an area where the institutional money will likely come back in and support the bio-tech stocks, until then the bounces in the sector are likely to be just small rallies from an oversold condition.

    Nicholas Santiago
    InTheMoneyStocks

  • Alcoa Inc (NYSE:AA) is the best performing Dow Jones Industrial Average stock of 2014. It has been a monster, hitting a new 52 week high today of $13.18. While this seems great, it may have put in a top today. After surging early in the day, the stock has reversed and gone negative. There is a possible topping tail on the daily chart and it is up 50% in the last six months. This has the makings of a top written all over it. A pull back to $11.00 is likely should the markets begin to sell in the coming weeks.

    Gareth Soloway
    InTheMoneyStocks

  • Netflix, Inc. (NASDAQ:NFLX) continues to decline today. The stock is trading at $351.62 -7.25 (- 2.02%). After topping out at $458 a share, the stock has fallen by 23% in a month. Many investors are too scared to go near it, just after they were buying at the all time highs so eagerly. Smart investors are starting to look for a great entry. The level for entry is a major gap fill along with the 200 moving average. This level is $334. Expect a strong bounce off this level for a week or two.

    Gareth Soloway
    InTheMoneyStocks

  • Facebook Inc (NASDAQ:FB) has been taking a beating in the last few weeks. The stock topped out at $72.59 before dumping to a low today of $57.98. This is a dramatic $17.61 (24%) fall. So where does this become a no brainer buy? The level is $53.25 if it hits in the next three trading days. This level is based on a key gap fill as well as a time factor. Some of you may ask why it must hit it in the next three trading days? That is the time factor which is unbelievably important to any profitable trade.

    Gareth Soloway
    InTheMoneyStocks

    Sentiment: Buy

  • Three weeks ago when the iShares NASDAQ Biotechnology Index (NASDAQ:IBB) was trading at $275.00, I was on 820 AM News Talk Radio in Florida, talking about the one sector which was a true bubble in this market. That sector was the biotechnology sector. At that time, the financial media on CNBC continued to talk about it as a buy, telling viewers it was in an 'uptrend'. Today biotech index IBB hit a low today of $232.84. This is a massive collapse of $42 (15%).

    Today, the only thing the media is talking about is the biotech collapse. These 'analysts' and 'commentators' are always late to the trade and ultimately lose people money. The fact that they are talking about it now means we are close to a bounce on the biotech index.

    Gareth Soloway
    InTheMoneyStocks

  • Facebook Inc (NASDAQ:FB) has a classic bear flag that is forming under the 20 moving average on the daily chart. This is one of the better patterns you will see and ultimately tells of much further downside on the stock. Even today, the stock is underperforming a market that is flat. Facebook is trading at $68.21, -0.98 (-1.42%). Key supports will be $58.85 and $53.45.

    Gareth Soloway
    InTheMoneyStocks

  • In 2012, Apple Inc. (NASDAQ:AAPL) saw countless upgrades when the stock was trading at $700 a share. The stock never went higher and has since collapsed as low as $387.00 before stabilizing in the $500 range. This shameful action by analysts should be a learning experience for all investors. The lesson? Always be skeptical of upgrades at all-time highs or downgrades at all-time lows. Most analysts are no better than an average investor and often times can have ulterior motives.

    History appears to be repeating itself again. Facebook Inc (NASDAQ:FB) has seen multiple upgrades in recent weeks including yesterday, when UBS upgraded the stock to a $90 price target. Sound familiar? In 2012, when Apple was trading at $700, it saw upgrades to $1000 price targets and beyond. Be aware of this as it may be telling us of a long term top on the stock.

    Gareth Soloway
    InTheMoneyStocks

  • International Business Machines Corp. (NYSE:IBM) is slamming into a key level of resistance. This level is at $181.15. Based on this resistance level and multiple other factors, IBM is an easy short here for a multi-day pullback. A $177.00 target can be used. Enjoy and profit.

    Gareth Soloway

  • Sugar has been in one of the ugliest bear markets in recent history. It has fallen to epic lows, not seen since 2010. An over supply from South American countries has flooded the market and is making it almost impossible for U.S. farmers to turn a profit. Just last week, for the first time in what seems like forever, sugar popped higher by about 10%. Over the last few days it has started to trail lower again. Please note the chart below.

    Based on the price action in the last week, sugar is now a buy. For easy access, follow the iPath DJ-UBS Sugar Subindex Total Return Sm Index ETN (NYSEARCA:SGG). The SGG is a tracking ETN an easy way to follow the sugar price action. The current pull back off the 10% pop is a classic in-spirit-of bull flag. The price target for a buy is $52.00. This also matches up with the 20 moving average.

    Upside potential on the SGG from the $52.00 level is target of $56.50. Should it close below the recent lows of $49.25, a stop out should be used. This is one of the sweetest trade setups I see in the market currently. Enjoy!

    Gareth Soloway
    InTheMoneyStocks

    Sentiment: Buy

  • A majority of earnings from retailers have been horrid this quarter. Whether it is Lululemon Athletica inc. (NASDAQ:LULU), Sears Holdings Corp (NASDAQ:SHLD) or Elizabeth Arden, Inc. (NASDAQ:RDEN), there has not been many bright spots. One stock that gave Wall Street a surprise was Abercrombie & Fitch Co. (NYSE:ANF). After reporting, the stock surged from $33.21 to a high of $38.15. As the markets have collapsed in 2014, ANF has dropped sharply. This gives us an opportunity to buy a retailer who is actually performing for a great price. This looks solid at its current price of $32.52, -0.64 (-1.93%).

    Gareth Soloway

    Sentiment: Buy

JCP
8.11+0.02(+0.28%)11:44 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.